Novartis AG

06/21/2022 | Press release | Distributed by Public on 06/21/2022 17:08

Novartis plans to petition the U.S. Court of Appeals for the Federal Circuit for further review to uphold validity of the Gilenya® (fingolimod) dosing regimen patent